Loading...
  • dose
  • We observed that loss of Btg1 increased the tumor incidence of Ikzf1+/- mice in a dose-dependent manner. (eur.nl)
  • We reasoned that small doses - for these mice, an equivalent to one percent of the dose used in humans - would turn on just enough autophagy in neurons that the cells would clear malfunctioning proteins, and nothing else. (news-medical.net)
  • bone marrow
  • Postmortem analysis revealed splenomegaly and generalized lymphadenopathy (fig. S1), and in 26 out of 29 MLL-ENL mice, L1 type lymphoblasts were found in the blood and bone marrow (BM), which is consistent with the development of ALL. (sciencemag.org)
  • By implanting ceramic scaffolds coated with human mesenchymal stromal cells into immune-deficient mice, we were able to mimic the human bone marrow niche. (bloodjournal.org)
  • We previously demonstrated that an inflammatory chemokine, CCL3, preferentially acts on normal hematopoietic stem/progenitor cells (HSPCs) and crucially contributes to the maintenance of leukemia initiating cells (LICs) in bone marrow (BM) during the initiation process of CML. (bloodjournal.org)
  • When the mice in this study were treated with the HDAC1,2 inhibitor or the HDAC1,2/doxorubicin combination, their bone marrow started turning from pale to red, indicating the white blood cells were being replaced with red blood cells. (eurekalert.org)
  • pathway
  • When an existing drug was given that blocks the de novo pathway in a leukemia cell, the dCTP nucleotide was still produced by the nucleoside salvage pathway, and the leukemia cell survived. (eurekalert.org)
  • Proteins
  • Researchers at Georgetown University Medical Center have used tiny doses of a leukemia drug to halt accumulation of toxic proteins linked to Parkinson's disease in the brains of mice. (news-medical.net)
  • therapeutic
  • But researchers at Huntsman Cancer Institute (HCI) at the University of Utah have discovered new science, published this week in the journal Leukemia , that could provide better therapeutic options for patients. (eurekalert.org)
  • Viral
  • Gross, L. 1958 Viral etiology of "spontaneous" mouse leukemia: A review. (springer.com)
  • This DNA segment and other defined viral subgenomic fragments have been used as 32P-labeled probes to identify and analyze the structure of integrated ecotropic viral DNA sequences in uninfected mouse genomes. (semanticscholar.org)
  • patients
  • In a large discovery cohort of 533 childhood B-cell precursor acute lymphoblastic leukemia patients, we observed that single-copy losses of BTG1 were significantly enriched in IKZF1-deleted B-cell precursor acute lymphoblastic leukemia (P=0.007). (eur.nl)
  • In contrast, other copy number losses commonly observed in B-cell precursor acute lymphoblastic leukemia, such as CDKN2A/B, PAX5, EBF1 or RB1, did not affect the outcome of IKZF1-deleted acute lymphoblastic leukemia patients. (eur.nl)
  • The mice used in this study over-express alpha-Synuclein, the protein that builds up in Lewy bodies in Parkinson's disease and dementia patients and which is found in many other neurodegenerative diseases. (news-medical.net)
  • toxic
  • The treated mice didn't get sick from the drug, and we did not see any apparent toxic side-effects in them. (eurekalert.org)
  • researchers
  • During the experiments, the researchers injected each mouse with about 600 nanograms of D12-PGJ3 each day for a week. (futurity.org)
  • development
  • Since this agent is vertically transmitted, it is expected that germfree mice would also develop leukemia, unless the presence of a microbial flora, or other horizontally transmitted viruses, contribute to its development. (springer.com)
  • Combination
  • After a comprehensive analysis of how the drug worked, Bhaskara tested the HDAC1,2 inhibitor in patient samples and mice and saw encouraging results, either alone or in combination with a chemotherapy drug called doxorubicin. (eurekalert.org)
  • We actually show in the patient-derived mouse models that using the combination of drugs, or HDAC1,2 inhibitor alone, is sufficient to decrease the leukemia load. (eurekalert.org)
  • models
  • In mouse models, a 50-70 percent reduction in leukemia was observed with either HDAC1,2 inhibitor alone or when the inhibitor was used with doxorubicin. (eurekalert.org)